Chinook therapeutics revenue
WebApr 6, 2024 · 9 brokers have issued 1 year price objectives for Chinook Therapeutics' shares. Their KDNY share price forecasts range from $30.00 to $44.00. On average, they predict the company's stock price to reach $38.00 in the next twelve months. This suggests a possible upside of 64.1% from the stock's current price. WebMay 12, 2024 · Revenue – Revenue for the quarter ended March 31, 2024 was $2.7 million compared to $0.4 million for the same period in 2024. The increase was primarily due to revenue recognized under Chinook ...
Chinook therapeutics revenue
Did you know?
WebCumulative List of Organizations Described in Section 170 (c) of the Internal Revenue Code of 1954, Volumes 1-2. United States. Internal Revenue Service. Department of the … WebFeb 25, 2024 · The revenue for CHK-336 is expected to reach an annual total of $24 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along …
WebMar 25, 2024 · This is a summary of current ratings and price targets for Bio-Path and Chinook Therapeutics, as provided by MarketBeat. Bio-Path presently has a consensus price target of $9.00, indicating a ... WebAndrew is chief scientific officer at Chinook Therapeutics, overseeing the discovery research, non-clinical development and translational medicine teams. Andrew joined …
WebFeb 27, 2024 · The higher revenue amounts in 2024 were primarily due to $41.2 million non-cash revenue recognized under Chinook’s license agreement with SanReno Therapeutics and a $10.0 million milestone ... WebApr 9, 2024 · Chinook Therapeutics Trading Down 0.8 %. Shares of KDNY opened at $22.12 on Friday. The firm’s 50-day moving average is $23.02 and its two-hundred day moving average is $22.82.
WebApr 13, 2024 · Chinook Therapeutics, Inc. SEATTLE, April 13, 2024 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and ...
WebFeb 24, 2024 · Chinook Therapeutics is a biotechnology company developing precision medicines for kidney diseases. The company applies its proprietary discovery platform, which leverages single-cell RNA sequencing, human-derived organoids, and new translational models, to discover and develop therapeutics with novel mechanisms of … dungeons and dragons lawyerWebAug 8, 2024 · Revenue – Revenue for the quarter and six months ended June 30, 2024 was $0.4 million and $3.1 million, respectively, compared to less than $0.1 million and $0.4 million for the same periods in ... dungeons and dragons legends of baldur\u0027s gateWebRevenue in 2024 (TTM): $6.12 M According to Chinook Therapeutics 's latest financial reports the company's current revenue (TTM) is $6.12 M . In 2024 the company made a … dungeons and dragons leather armorWebFeb 27, 2024 · Chinook Therapeutics GAAP EPS of -$0.90 misses by $0.11, revenue of $0.51M beats by $0.41M Feb. 27, 2024 4:05 PM ET Chinook Therapeutics, Inc. (KDNY) By: Gaurav Batavia , SA News Editor dungeons and dragons lightWebApr 9, 2024 · The firm's quarterly revenue was down 90.0% on a year-over-year basis. Analysts predict that Chinook Therapeutics will post -3.19 EPS for the current year. Insider Transactions at Chinook Therapeutics. In related news, COO Tom Frohlich sold 4,566 shares of Chinook Therapeutics stock in a transaction on Tuesday, January 31st. The … dungeons and dragons legends of baldurWebFeb 26, 2024 · Based on Chinook Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $2.5 million and a GAAP net loss of $55.98 million. dungeons and dragons loot crateWebChinook Therapeutics revenue is $54 M. How many employees does Chinook Therapeutics have? Chinook Therapeutics has 138 employees. Where is Chinook Therapeutics headquarters located? Chinook Therapeutics headquarters are located in 400 Fairview Avenue North Ste 900, Seattle, Washington, 98109, United States . dungeons and dragons lingo